San45
San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C194H309N51O57S2
- 分子量:4331.97
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
体外実験
San45 (serial dilutions; 30 min) is a potent, nonselective dual amylin and calcitonin receptor agonist (DACRA) with similar potency at AMY3R (pEC50 = 10.66) and CTR (pEC50 = 10.45) in HEK293-Flp-In cells[1].
San45 (serial dilutions; 30 min) maintains potent, nonselective DACRA activity across CTR, AMY1R, and AMY3R in COS-1 cells, with pEC50 values of 9.19 (CTR), 8.83 (AMY1R), and 9.34 (AMY3R)[1].
San45 (4 μM (AMY3R complex); 2 μM (CTR complex)) binds to AMY3R via a distorted bypass conformation and to CTR via an alternative CT-like conformation, stabilized by its lipid modification, supporting its nonselective DACRA activity[1].
San45 (serial dilutions; measured over cycles) exhibits prolonged cAMP signaling duration in COS-7 cells expressing AMY1R, likely due to its lipid modification[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
化学情報
-
分子量 4331.97
-
分子式 C194H309N51O57S2
-
配列
Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Lys(γGlu-C16 acid)-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr (Disulfide bridge:Cys2-Cys7)
-
シーケンスの短縮
KCNTATCATQRLANFLVHSS-Lys(γGlu-C16 acid)-NFGPILPPTNVGSNTY (Disulfide bridge:Cys2-Cys7)
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)